What predicts attrition in second step medication treatments for depression?: a STAR*D Report
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Attrition rates are high during treatment for major depressive disorder (MDD), and patients who drop out are less likely to reach remission. This report evaluates the incidence, timing, and predictors of attrition during second-step medication treatment. Outpatients in the multisite Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study receiving a medication augmentation (n=563) or medication switch (n=723) for non-psychotic MDD after an unsatisfactory outcome with citalopram were evaluated to determine attrition rates and pretreatment sociodemographic or clinical predictors of attrition. Twenty percent of participants receiving a medication augmentation and 27% receiving a medication switch dropped out before 12 wk in the second treatment step. Remission rates were lower for dropouts [7% vs. 43% (medication augmentation); 12% vs. 31% (medication switch)]. For medication augmentation, Black and other non-Caucasian races, Hispanic ethnicity, younger age, family history of drug abuse, concurrent drug abuse, sociodemographic disadvantage, less symptom improvement with initial citalopram treatment, and greater symptom severity when beginning augmentation were associated with attrition. For medication switch, Black and other non-Caucasian races, younger age, more melancholic features, and lower exit doses but more severe side-effects with citalopram treatment were associated with attrition. Minority status, younger age, and greater difficulty with the first treatment step are risk factors for attrition in the second treatment step. Focus on patients with attrition risk factors for medication augmentation or switch strategies may enhance retention and improve outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 3×
“However, two-thirds of MDD patients do not achieve remission with a first-step treatment (Trivedi et al., 2006b).”
InfluentialSelf-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 1×
“Depressive symptom severity was evaluated at entry into level 1 and each subsequent level using the HAMD17, the 16-item Quick Inventory of Depressive Symptomatology – Clinician-rated (QIDS-C16), and the QIDS Self-Report (QIDS-SR16 ; Rush et al., 2000, 2003, 2006a; Trivedi et al., 2004).”
Self-citationThe Work and Social Adjustment Scale: a simple measure of impairment in functioning
Mundt, J. C., Marks, I. M., Shear, M. K., & Greist, J. M. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.461 · Cited by 2,515
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177 · cited 1×
“…assessor, masked to treatment, obtained the HAMD17 (primary outcome measure) and the 30-item Inventory of Depressive Symptomatology – Clinician-rated (IDS-C30 ; Rush et al., 1996, 2000 ; Trivedi et al., 2004) via telephone interviews (in English or Spanish) to measure depressive symptom severity.”
Self-citationMiller, M. D., Paradis, C. F., Houck, P. R., Mazumdar, S., Stack, J. A., Rifai, A. H., Mulsant, B., & Reynolds, C. F. (1992) · Psychiatry Research · doi:10.1016/0165-1781(92)90005-n · Cited by 1,990 · cited 2×
“life (step 2 entry) SF-12 Physical 45.6 (12.4) 47.4 (12) 0.2497 43.4 (12.4) 45.8 (12.7) 0.0673 SF-12 Mental 32.2 (9.5) 32.7 (9.3) 0.6413 30.9 (10.7) 29 (9.4) 0.0486 General medical comorbidities (CIRS) Categories endorsed 2.9 (2.2) 3 (2.3) 0.5586 3.1 (2.2) 3.4 (2.5) 0.1757 Total score 4.2 (3.8) 4.4 (3.9) 0.6956 4.5 (3…”
InfluentialSequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076 · cited 1×
“The rationale and design of STAR*D are detailed elsewhere (Fava et al., 2003; Rush et al., 2004).”
Self-citationBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Self-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 3×
“However, two-thirds of MDD patients do not achieve remission with a first-step treatment (Trivedi et al., 2006b).”
InfluentialSelf-citationTRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968 · cited 4×
“…assessor, masked to treatment, obtained the HAMD17 (primary outcome measure) and the 30-item Inventory of Depressive Symptomatology – Clinician-rated (IDS-C30 ; Rush et al., 1996, 2000 ; Trivedi et al., 2004) via telephone interviews (in English or Spanish) to measure depressive symptom severity.”
InfluentialSelf-citationReport by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707 · cited 4×
“…Portions of this paper were presented in poster form at the International Society for Affective Disorders (ISAD), 4th Biennial Conference, Capetown, South Africa, March 2008. symptoms) and remission is associated with improved functioning andprognosis (Hirschfeld et al., 2002;Rush et al., 2006b).”
InfluentialSelf-citation
Cited by
Citalopram versus other anti-depressive agents for depression
Cipriani, A., Purgato, M., Furukawa, T. A., Trespidi, C., Imperadore, G., Signoretti, A., Churchill, R., Watanabe, N., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006534.pub2 · Cited by 311
Bewernick, B. H., Kayser, S., Gippert, S. M., Switala, C., Coenen, V. A., & Schlaepfer, T. E. (2017) · Brain stimulation · doi:10.1016/j.brs.2017.01.581 · Cited by 156
IsHak, W. W., Mirocha, J., James, D., Tobia, G., Vilhauer, J., Fakhry, H., Pi, S., Hanson, E., Nashawati, R., Peselow, E. D., et al. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12301 · Cited by 140
Kayser, S., Bewernick, B. H., Matusch, A., Hurlemann, R., Soehle, M., & Schlaepfer, T. E. (2015) · Psychological Medicine · doi:10.1017/s0033291714002244 · Cited by 94
Aggarwal, N. K., Glass, A., Tirado, A., Boiler, M., Nicasio, A., Alegría, M., Wall, M., & Lewis-Fernández, R. (2014) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2014.0132 · Cited by 90
Metadata
- Authors
- Warden, D., Rush, A. J., Wisniewski, S. R., Lesser, I. M., Kornstein, S. G., Balasubramani, G. K., Thase, M. E., Preskorn, S. H., Nierenberg, A. A., Young, E. A., Shores-Wilson, K., & Trivedi, M. H.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-07-09
- Volume
- 12
- Issue
- 04
- Pages
- 459
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2139431544
- Cited by
- 77
- References
- 18
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What predicts attrition in second step medication treatments for depression?: a STAR*D Report. https://app.cochat.ai/papers/10.1017/s1461145708009073
- The paper
- Warden, D., Rush, A. J., Wisniewski, S. R., Lesser, I. M., Kornstein, S. G., Balasubramani, G. K., Thase, M. E., Preskorn, S. H., Nierenberg, A. A., Young, E. A., Shores-Wilson, K., & Trivedi, M. H. (2009). What predicts attrition in second step medication treatments for depression?: a STAR*D Report. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145708009073
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.